Invention Grant
- Patent Title: Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
-
Application No.: US14864840Application Date: 2015-09-24
-
Publication No.: US09670201B2Publication Date: 2017-06-06
- Inventor: Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Göran Mattias Wennerstål , Li Xing , Edouard Zamaratski , Liying Zhang
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent A. David Joran
- Main IPC: C07D401/02
- IPC: C07D401/02 ; C07D401/10 ; A61K31/437 ; A61K31/4353 ; C07D471/04 ; C07D401/14
Abstract:
The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
Public/Granted literature
- US20160090381A1 Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof Public/Granted day:2016-03-31
Information query
